| Autor/in / Beteiligte Person: |
Shi, M ; Yang, A ; Chow, E ; Lau, ESH ; Tam, CHT ; Kong, APS ; Luk, AOY ; Ma, RCW ; Cheung, CMT ; Chan, JCN ; Chan, AWS |
| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Letter; Research Support, Non-U.S. Gov't
- Language: English
- [J Eur Acad Dermatol Venereol] 2023 Mar; Vol. 37 (3), pp. e375-e377. <i>Date of Electronic Publication: </i>2022 Nov 25.
- MeSH Terms: Diabetes Mellitus, Type 2* / complications ; Diabetes Mellitus, Type 2* / drug therapy ; Dipeptidyl-Peptidase IV Inhibitors* / adverse effects ; Pemphigoid, Bullous* / chemically induced ; Pemphigoid, Bullous* / genetics ; Humans ; East Asian People ; Genetic Predisposition to Disease
- References: International Diabetes Federation. IDF diabetes atlas tenth edition, https://www.diabetesatlas.org (2021). Accessed 8 January 2022. ; Yang A, Wu H, Lau ESH, Ma RCW, Kong APS, So WY, et al. Trends in glucose-lowering drug use, glycemic control, and severe hypoglycemia in adults with diabetes in Hong Kong, 2002-2016. Diabetes Care. 2020;43(12):2967-74. ; Persson MSM, Harman KE, Vinogradova Y, Langan SM, Hippisley-Cox J, Thomas KS, et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study. Br J Dermatol. 2021;184(1):68-77. ; Cortes B, Khelifa E, Clivaz L, Cazzaniga S, Saurat JH, Naldi L, et al. Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study. Dermatology. 2012;225(4):320-5. ; Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26(2):249-53. ; Zhang J, Wang G. Genetic predisposition to bullous pemphigoid. J Dermatol Sci. 2020;100(2):86-91. ; Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, et al. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol. 2018;138(5):1201-4. ; Chan JCN, Lim LL, Luk AOY, Ozaki R, Kong APS, Ma RCW, et al. From Hong Kong diabetes register to JADE program to RAMP-DM for data-driven actions. Diabetes Care. 2019;42(11):2022-31. ; Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, et al. Gene map of the extended human MHC. Nat Rev Genet. 2004;5(12):889-99. ; Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.
- Grant Information: T12-402/13N Hong Kong Government Research Grants Committee Theme-based Research Scheme; R4012-18 Research Impact Fund
- Substance Nomenclature: 0 (Dipeptidyl-Peptidase IV Inhibitors)
- Entry Date(s): Date Created: 20221117 Date Completed: 20230215 Latest Revision: 20230221
- Update Code: 20231215
|
